Reactivation of p53 by novel MDM2 inhibitors: Implications for pancreatic cancer therapy

Current Cancer Drug Targets

Volumn 10, Issue 3, 2010, Pages 319-331

  Azmi, A S ^a   Philip, P A ^a   Aboukameel, A ^a   Wang, Z ^a   Banerjee, S ^a   Zafar, S F ^a   Goustin, A S ^a   Almhanna, K ^a   Yang, D ^b   Sarkar, F H ^a   Mohammad, R M ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Ascenta Therapeutics   (United States)

Author keywords

Apoptosis; Cell cycle arrest; MDM2 and p53; Pancreatic cancer; Small molecule inhibitors

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 1; GEMCITABINE; KU ANTIGEN; MI 219; MI 319; PROTEIN BAX; PROTEIN MDM2; PROTEIN MDM2 INHIBITOR; PROTEIN P53; SIRTUIN 2; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ACETYLATION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL GROWTH; DRUG POTENTIATION; DRUG PROTEIN BINDING; GROWTH INHIBITION; HUMAN; IMMUNOPRECIPITATION; NONHUMAN; PANCREAS CANCER; PROTEIN PROTEIN INTERACTION; SURFACE PLASMON RESONANCE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTIGENS, NUCLEAR; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DEOXYCYTIDINE; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; IMMUNOPRECIPITATION; INDOLES; MICE; MICE, INBRED ICR; MICE, SCID; PANCREATIC NEOPLASMS; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; RNA INTERFERENCE; SIRTUIN 1; SPIRO COMPOUNDS; SURFACE PLASMON RESONANCE; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77952800865     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800910791190229     Document Type: Article

References (55)

1. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Thun, M. J. Cancer statistics, 2009. CA Cancer J. Clin. 2009, 59, 225-249.
2. Levine, A. J. p53, the cellular gatekeeper for growth and division. Cell 1997, 88, 323-331.
3. Vogelstein, B.; Lane, D.; Levine, A. J. Surfing the p53 network. Nature 2000, 408, 307-310.
4. Barton, C. M.; Staddon, S. L.; Hughes, C. M.; Hall, P. A.; O'Sullivan, C.; Kloppel, G.; Theis, B.; Russell, R. C.; Neoptolemos, J.; Williamson, R. C. Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer. Br. J. Cancer 1991, 64, 1076-1082.
5. Vazquez, A.; Bond, E. E.; Levine, A. J.; Bond, G. L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 2008, 7, 979-987.
6. Lowe, S. W. Cancer therapy and p53. Curr. Opin. Oncol. 1995, 7, 547-553.
7. Lowe, S. W.; Bodis, S.; McClatchey, A.; Remington, L.; Ruley, H. E.; Fisher, D. E.; Housman, D. E.; Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science 1994, 266, 807-810.
8. Lowe, S. W.; Bodis, S.; Bardeesy, N.; McClatchey, A.; Remington, L.; Ruley, H. E.; Fisher, D. E.; Jacks, T.; Pelletier, J.; Housman, D. E. Apoptosis and the prognostic significance of p53 mutation. Cold Spring Harb. Symp. Quant. Biol. 1994, 59, 419-426.
9. Brooks, C. L.; Gu, W. p53 ubiquitination: Mdm2 and beyond. Mol. Cell 2006, 21, 307-315.
10. Haupt, Y.; Barak, Y.; Oren, M. Cell type-specific inhibition of p53-mediated apoptosis by mdm2. EMBO J. 1996, 15, 1596-1606.
11. Lahav, G. Oscillations by the p53-Mdm2 feedback loop. Adv. Exp. Med. Biol. 2008, 641, 28-38.
12. Bose, I.; Ghosh, B. The p53-MDM2 network: from oscillations to apoptosis. J. Biosci. 2007, 32, 991-997.
13. Zhang, Z.; Wang, H.; Li, M.; Rayburn, E.; Agrawal, S.; Zhang, R. Novel MDM2 p53-independent functions identified through RNA silencing technologies. Ann. N. Y. Acad. Sci. 2005, 1058, 205-214.
14. Bordone, L.; Guarente, L. Calorie restriction, SIRT1 and metabolism: understanding longevity. Nat. Rev. Mol. Cell Biol. 2005, 6, 298-305.
15. Campisi, J. Suppressing cancer: the importance of being senescent. Science 2005, 309, 886-887.
16. Tang, Y.; Zhao, W.; Chen, Y.; Zhao, Y.; Gu, W. Acetylation is indispensable for p53 activation. Cell 2008, 133, 612-626.
17. Brooks, C. L.; Gu, W. How does SIRT1 affect metabolism, senescence and cancer? Nat. Rev. Cancer 2009, 9, 123-128.
18. Li, Y.; Yokota, T.; Gama, V.; Yoshida, T.; Gomez, J. A.; Ishikawa, K.; Sasaguri, H.; Cohen, H. Y.; Sinclair, D. A.; Mizusawa, H.; Matsuyama, S. Bax-inhibiting peptide protects cells from polyglutamine toxicity caused by Ku70 acetylation. Cell Death Differ. 2007, 14, 2058-2067.
19. Gama, V.; Gomez, J. A.; Mayo, L. D.; Jackson, M. W.; Danielpour, D.; Song, K.; Haas, A. L.; Laughlin, M. J.; Matsuyama, S. Hdm2 is a ubiquitin ligase of Ku70-Akt promotes cell survival by inhibiting Hdm2-dependent Ku70 destabilization. Cell Death Differ. 2009, 16, 758-769.
20. Klein, C.; Vassilev, L. T. Targeting the p53-MDM2 interaction to treat cancer. Br. J. Cancer 2004, 91, 1415-1419.
21. Secchiero, P.; di Iasio, M. G.; Gonelli, A.; Zauli, G. The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr. Pharm. Des 2008, 14, 2100-2110.
22. Vassilev, L. T. Small-molecule antagonists of p53-MDM2 binding: research tools and potential therapeutics. Cell Cycle 2004, 3, 419-421.
23. Brown, C. J.; Lain, S.; Verma, C. S.; Fersht, A. R.; Lane, D. P. Awakening guardian angels: drugging the p53 pathway. Nat. Rev. Cancer 2009, 9, 862-873.
24. Wang, W.; Kim, S. H.; El-Deiry, W. S. Small-molecule modulators of p53 family signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc. Natl. Acad. Sci. USA 2006, 103, 11003-11008.
25. Secchiero, P.; Corallini, F.; Gonelli, A.; Dell'Eva, R.; Vitale, M.; Capitani, S.; Albini, A.; Zauli, G. Antiangiogenic activity of the MDM2 antagonist nutlin-3. Circ. Res. 2007, 100, 61-69.
26. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Qiu, S.; Ding, Y.; Gao, W.; Stuckey, J.; Krajewski, K.; Roller, P. P.; Tomita, Y.; Parrish, D. A.; Deschamps, J. R.; Wang, S. Structure-based design of potent non-peptide MDM2 inhibitors. J. Am. Chem. Soc. 2005, 127, 10130-10131.
27. Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Wang, G.; Qiu, S.; Shangary, S.; Gao, W.; Qin, D.; Stuckey, J.; Krajewski, K.; Roller, P. P.; Wang, S. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem. 2006, 49, 3432-3435.
28. Azmi, A. S.; Wang, Z.; Burikhanov, R.; Rangnekar, V. M.; Wang, G.; Chen, J.; Wang, S.; Sarkar, F. H.; Mohammad, R. M. Critical role of prostate apoptosis response-4 in determining the sensitivity of pancreatic cancer cells to small-molecule inhibitor-induced apoptosis. Mol. Cancer Ther. 2008, 7, 2884-2893.
29. Azmi, A. S.; Ahmad, A.; Banerjee, S.; Rangnekar, V. M.; Mohammad, R. M.; Sarkar, F. H. Chemoprevention of pancreatic cancer: characterization of Par-4 and its modulation by 3,3' diindolylmethane (DIM). Pharm. Res. 2008, 25, 2117-2124.
30. Hsu, S. M. Clinical applications of immunoperoxidase technique. R. I. Med. J. 1979, 62(11), 447-452.
31. Shangary, S.; Qin, D.; McEachern, D.; Liu, M.; Miller, R. S.; Qiu, S.; Nikolovska-Coleska, Z.; Ding, K.; Wang, G.; Chen, J.; Bernard, D.; Zhang, J.; Lu, Y.; Gu, Q.; Shah, R. B.; Pienta, K. J.; Ling, X.; Kang, S.; Guo, M.; Sun, Y.; Yang, D.; Wang, S. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl. Acad. Sci. USA 2008, 105, 3933-3938.
32. Eisold, S.; Linnebacher, M.; Ryschich, E.; Antolovic, D.; Hinz, U.; Klar, E.; Schmidt, J. The effect of adenovirus expressing wild-type p53 on 5-fluorouracil chemosensitivity is related to p53 status in pancreatic cancer cell lines. World J. Gastroenterol. 2004, 10, 3583-3589.
33. Fujioka, S.; Schmidt, C.; Sclabas, G. M.; Li, Z.; Pelicano, H.; Peng, B.; Yao, A.; Niu, J.; Zhang, W.; Evans, D. B.; Abbruzzese, J. L.; Huang, P.; Chiao, P. J. Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. J. Biol. Chem. 2004, 279, 27549-27559.
34. Bouvet, M.; Bold, R. J.; Lee, J.; Evans, D. B.; Abbruzzese, J. L.; Chiao, P. J.; McConkey, D. J.; Chandra, J.; Chada, S.; Fang, B.; Roth, J. A. Adenovirus-mediated wild-type p53 tumor suppressor gene therapy induces apoptosis and suppresses growth of human pancreatic cancer [seecomments]. Ann. Surg. Oncol. 1998, 5, 681-688.
35. Sui, X.; Shin, S.; Zhang, R.; Firozi, P. F.; Yang, L.; Abbruzzese, J. L.; Reddy, S. A. Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells. Oncogene 2009, 28, 709-720.
36. Zauli, G.; Rimondi, E.; Corallini, F.; Fadda, R.; Capitani, S.; Secchiero, P. MDM2 antagonist Nutlin-3 suppresses the proliferation and differentiation of human pre-osteoclasts through a p53-dependent pathway. J. Bone Miner. Res. 2007, 22, 1621-1630.
37. Macleod, K. F.; Sherry, N.; Hannon, G.; Beach, D.; Tokino, T.; Kinzler, K.; Vogelstein, B.; Jacks, T. p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. Genes Dev. 1995, 9, 935-944.
38. Shangary, S.; Ding, K.; Qiu, S.; Nikolovska-Coleska, Z.; Bauer, J. A.; Liu, M.; Wang, G.; Lu, Y.; McEachern, D.; Bernard, D.; Bradford, C. R.; Carey, T. E.; Wang, S. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer. Mol. Cancer Ther. 2008, 7, 1533-1542.
39. Burris, H. A., III; Moore, M. J.; Andersen, J.; Green, M. R.; Rothenberg, M. L.; Modiano, M. R.; Cripps, M. C.; Portenoy, R. K.; Storniolo, A. M.; Tarassoff, P.; Nelson, R.; Dorr, F. A.; Stephens, C. D.; Von Hoff, D. D. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J. Clin. Oncol. 1997, 15, 2403-2413.
40. Vaziri, H.; Dessain, S. K.; Ng, E. E.; Imai, S. I.; Frye, R. A.; Pandita, T. K.; Guarente, L.; Weinberg, R. A. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 107, 149-159.
41. Smith, J. Human Sir2 and the 'silencing' of p53 activity. Trends Cell Biol. 2002, 12, 404-406.
42. Yamakuchi, M.; Lowenstein, C. J. MiR-34, SIRT1 and p53: the feedback loop. Cell Cycle 2009, 8, 712-715.
43. Yamakuchi, M.; Ferlito, M.; Lowenstein, C. J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. USA 2008, 105, 13421-13426.
44. Wang, Z.; Sengupta, R.; Banerjee, S.; Li, Y.; Zhang, Y.; Rahman, K. M.; Aboukameel, A.; Mohammad, R.; Majumdar, A. P.; Abbruzzese, J. L.; Sarkar, F. H. Epidermal growth factor receptorrelated protein inhibits cell growth and invasion in pancreatic cancer. Cancer Res. 2006, 66, 7653-7660.
45. Hollstein, M.; Moeckel, G.; Hergenhahn, M.; Spiegelhalder, B.; Keil, M.; Werle-Schneider, G.; Bartsch, H.; Brickmann, J. On the origins of tumor mutations in cancer genes: insights from the p53 gene. Mutat. Res. 1998, 405, 145-154.
46. Hollstein, M.; Rice, K.; Greenblatt, M. S.; Soussi, T.; Fuchs, R.; Sorlie, T.; Hovig, E.; Smith-Sorensen, B.; Montesano, R.; Harris, C. C. Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res. 1994, 22, 3551-3555.
47. Mohammad, R. M.; Wu, J.; Azmi, A. S.; Aboukameel, A.; Sosin, A.; Wu, S.; Yang, D.; Wang, S.; Al-Katib, A. M. An MDM2 antagonist (MI-319) restores p53 functions and increases the life span of orally treated follicular lymphoma bearing animals. Mol. Cancer 2009, 8, 115.
48. Grochola, L. F.; Muller, T. H.; Bond, G. L.; Taubert, H.; Udelnow, A.; Wurl, P. MDM2 SNP309 Associates With Accelerated Pancreatic Adenocarcinoma Formation. Pancreas 2010, 29, 76-80.
49. Asomaning, K.; Reid, A. E.; Zhou, W.; Heist, R. S.; Zhai, R.; Su, L.; Kwak, E. L.; Blaszkowsky, L.; Zhu, A. X.; Ryan, D. P.; Christiani, D. C.; Liu, G. MDM2 promoter polymorphism and pancreatic cancer risk and prognosis. Clin. Cancer Res. 2008, 14, 4010-4015.
50. Stommel, J. M.; Wahl, G. M. A new twist in the feedback loop: stress-activated MDM2 destabilization is required for p53 activation. Cell Cycle 2005, 4, 411-417.
51. Gu, W.; Luo, J.; Brooks, C. L.; Nikolaev, A. Y.; Li, M. Dynamics of the p53 acetylation pathway. Novartis Found. Symp. 2004, 259, 197-205.
52. Ito, A.; Kawaguchi, Y.; Lai, C. H.; Kovacs, J. J.; Higashimoto, Y.; Appella, E.; Yao, T. P. MDM2-HDAC1-mediated deacetylation of p53 is required for its degradation. EMBO J. 2002, 21, 6236-6245.
53. Hasegawa, K.; Yoshikawa, K. Necdin regulates p53 acetylation via Sirtuin1 to modulate DNA damage response in cortical neurons. J. Neurosci. 2008, 28, 8772-8784.
54. Wolkersdorfer, G. W.; Thiede, C.; Fischer, R.; Ehninger, G.; Haag, C. Adenoviral p53 gene transfer and gemcitabine in three patients with liver metastases due to advanced pancreatic carcinoma. HPB (Oxford) 2007, 9, 16-25.
55. Azmi, A. S.; Aboukameel, A.; Banerjee, S.; Wang, Z.; Mohammad, M.; Wu, J.; Wang, S.; Yang, D.; Philip, P. A.; Sarkar, F. H.; Mohammad, R. M. MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 function. Eur. J. Cancer 2010, 46, 1122-1131.